Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: ...

Q4 2024 Earnings Call Transcript November 26, 2024 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) had its price target trimmed by Citigroup from $27.00 to $26.00 in a ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) had its target price trimmed by Sanford C. Bernstein from $27.00 to $24 ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2024 fiscal year ended September 30, 2024. The Company is hosting a conference call today, November 26, 2024, ...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...

Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...

Morgan Stanley analyst Michael Ulz maintained a Hold rating on Arrowhead Pharmaceuticals (ARWR – Research Report) today and set a price target ...

Q4 2024 Earnings Conference Call November 26, 2024 4:30 PM ET. Company Participants. Vince Anzalone - VP, IR Chris Anzalone - Preside ...

Sarepta Therapeutics said it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of experimental RNA-based ...

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...

Goldman has recently initiated Arrowhead Pharmaceuticals Inc (ARWR) stock to Neutral rating, as announced on June 5, 2024, according to Finviz. Earlier, on December 4, 2023, BofA Securities had ...